

Tazemetostat (TAZVERIK)

Criteria for Use

September 2022

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at the [PBM INTRAnet](#) site for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive tazemetostat.

- Positive Hepatitis B surface antigen with abnormal LFTs. Tbili >1.5x Upper Limit of Normal and/or Alk phos, ALT and AST > 3x Upper Limit of Normal (or > 5x Upper Limit of Normal if liver metastasis)
- Positive Hepatitis C Virus RNA with abnormal LFTs. Tbili > 1.5x Upper Limit of Normal and/or Alk phos, ALT and AST > 3x Upper Limit of Normal (or > 5x Upper Limit of Normal if liver metastasis)
- Unmanageable drug or food interaction
- Unable to take oral medications due to malabsorption syndrome or other gastrointestinal syndrome

Inclusion Criteria

One of the following criteria must be met.

- Metastatic or locally advanced epithelioid sarcoma, not eligible for complete resection
- Relapsed or refractory follicular lymphoma, with an EZH2 mutation and received at least 2 prior systemic therapies
- Relapsed or refractory follicular lymphoma, who have exhausted all treatment options

Additional Inclusion Criteria

All of the following criteria must be met.

- Care for the oncologic condition provided by VA or VA Community Care oncology provider
- Goals of care and role of Palliative Care consult have been discussed and documented
- Eastern Cooperative Oncology Group Performance status 0-2

Additional Inclusion Criteria

- For patients who can become pregnant: Pregnancy must be excluded prior to receiving tazemetostat
- For patients who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for 6 months after stopping treatment
- For patients with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for at least 3 months after stopping treatment
- Advise patients not to breastfeed during treatment and for 7 months following the last dose

Other Justification

- _____